Quicksilver Scientific

Free shipping over $50


Unsupported Browser

This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.

LipoCalm References

  1. Salcedo B. The comorbidity of anxiety and depression. National Alliance on Mental Illness. Available at: https://www.nami.org/Blogs/NAMI-Blog/January-2018/The-Comorbidity-of-Anxiety-and-Depression Accessed June 18, 2019.
  2. Ohayon M. Epidemiology of insomnia: What we know and what we still need to learn. Sleep Med Rev 2002: 6: 97–111.
  3. Andersen ML, Tufik S. Sleep and the modern society. J Sleep Disord Ther 2015; 4:e131.
  4. Wittchen, HU, Jacobi f et al. The size and burden of mental disorders and other disorders of the brain in Europe. European Neuropsychopharmacology 2010: 21(9), 655–679
  5. Baxter AJ, Scott KM et al. Global prevalence of anxiety disorders: a systematic review and meta‐regression. Psychological Medicine, 2013: 43(5), 897–910
  6. Kessler RC, Berglund P et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 Jun;62(6):593-602
  7. Chung KF, Lee CT et al. Sleep hygiene education as a treatment of insomnia: a systematic review and meta-analysis. Fam Pract. 2018 Jul 23;35(4):365-375
  8. Moloney ME, Ciciurkaite G et al. The medicalization of sleeplessness: Results of U.S. office visit outcomes, 2008-2015. SSM Popul Health. 2019 May 12;8:10038
  9. Bossini L, Collucia A. Off-Label trazodone prescription: evidence, benefits and risks. Curr Pharm Des. 2015;21(23):3343-51
  10. Ong JC, Shapiro SL et al. Mindfulness meditation and cognitive behavioral therapy for insomnia: a naturalistic 12-month follow-up Explore (NY). 2009 Jan-Feb;5(1):30-6
  11. Sarris J, McIntyre E et al. Plant-based medicines for anxiety disorders, Part 1: a review of preclinical studies. CNS Drugs. 2013 Mar;27(3):207-19
  12. Sarris J, Panossian A et el. Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence. European Neuropsychopharmacology 2011; 21: 841–860
  13. Auteri M, Zizzo MG et al. GABA and GABA receptors in the gastrointestinal tract: from motility to inflammation. Pharmacol Res. 2015 Mar;93:11-21
  14. McCorry LK. Physiology of the autonomic nervous system. Am J Pharm Educ. 2007 Aug 15; 71(4): 78.
  15. Nemeroff CB. The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull 2003;37:133-146
  16. Krystal JH, Sanacora G, et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 2002;7:S71-S80.
  17. Möhler H The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology. 2012 Jan;62(1):42-53
  18. Hasler G, van der Veen JW et al. Effect of acute psychological stress on prefrontal GABA concentration determined by proton magnetic resonance spectroscopy. Am J Psychiatry. 2010 Oct;167(10):1226-31
  19. Sheth C, Prescot AP. Reduced gamma-amino butyric acid (GABA) and glutamine in the anterior cingulate cortex (ACC) of veterans exposed to trauma. J Affect Disord. 2019 Apr 1;248:166-174
  20. Naaijen J, Bralten J et al. Glutamatergic and GABAergic gene sets in attention-deficit/hyperactivity disorder: association to overlapping traits in ADHD and autism Transl Psychiatry. 2017 Jan 10;7(1):e999
  21. Kwon HJ, Kim W et al. Association between GABA3 Gene Polymorphisms and Attention Deficit Hyperactivity Disorder in Korean Children. Psychiatry Investig. 2017 Sep;14(5):693-697
  22. Orser BA. Extrasynaptic GABA-A receptors are critical targets for sedative-hypnotic drugs. J Clin Sleep Med 2006;2:S12-S18
  23. Gottesmann C. GABA mechanisms and sleep. Neuroscience 2002;111:231-239
  24. Luppi PH, Peyron C. Not a single but multiple populations of GABAergic neurons control sleep. Sleep Med Rev. 2017 Apr;32:85-94
  25. Yoto A. Oral intake of γ-aminobutyric acid affects mood and activities of central nervous system during stressed condition induced by mental tasks. Amino Acids. 2012 Sep;43(3):1331-7
  26. Boonstra E, de Kleijn R et al. Neurotransmitters as food supplements: the effects of GABA on brain and behavior. Front Psychol. 2015 Oct 6;6:1520
  27. Petroff OA. GABA and glutamate in the human brain. Neuroscientist. 2002 Dec;8(6):562-73
  28. Lavefve L, Marasini D et al. Microbial Ecology of Fermented Vegetables and Non-Alcoholic Drinks and Current Knowledge on Their Impact on Human Health. Adv Food Nutr Res. 2019;87:147-185
  29. Unpublished data provided by Pharma Foods International LTD., Kyoto, Japan.
  30. Abdou AM, Higashiguchia S et al. Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans. Biofactors. 2006;26(3):201-8.
  31. Yamatsu A, Yamashita Y. Effect of oral γ-aminobutyric acid (GABA) administration on sleep and its absorption in humans. Food Sci Biotechnol. 2016 Apr 30;25(2):547-551
  32. D’Souza MS, Markou A. The “stop” and “go” of nicotine dependence: role of GABA and glutamate. Cold Spring Harb Perspect Med. ;3(6):a012146
  33. Banerjee N. Neurotransmitters in alcoholism: A review of neurobiological and genetic studies. Indian J Hum Genet. 2014;20(1):20–31
  34. Marrosu F, Serra A. Correlation between GABA(A) receptor density and vagus nerve stimulation in individuals with drug-resistant partial epilepsy. Epilepsy Res. 2003 Jun-Jul;55(1-2):59-70.
  35. Savage K, Firth J et al. GABA‐modulating phytomedicines for anxiety: A systematic review of preclinical and clinical evidence. Phytotherapy Research. 2018;32:3–18.
  36. Brock C, Whitehouse J et al. American skullcap (Scutellaria lateriflora): a randomised, double-blind placebo-controlled crossover study of its effects on mood in healthy volunteers. Phytother. Res. 2014;28 (5):692-698
  37. Felter HW, Lloyd JU. 1905. Scutellaria lateriflora. King’s American Dispensatory (19th edn). Ohio Valey Co: Cincinatti; 1739–4
  38. Ngan A, Conduit R et al. A double-blind, placebo-controlled investigation of the effects of Passiflora incarnata (passionflower) herbal tea on subjective sleep quality. Phytother Res. 2011 Aug;25(8):1153-9
  39. Gafner S, Bergeron C et al. Inhibition of [3H]-LSD binding to 5-HT7 receptors by flavonoids from Scutellaria lateriflora. J Nat Prod 2003; 66: 535–537
  40. Hui KM, Wang XH et al. Interaction of flavones from the roots of Scutellaria baicalensis with the benzodiazepine site. Planta Med 2000: 66: 91–93
  41. Wolfson P, Hoffmann DL. An investigation into the efficacy of Scutellaria lateriflora in healthy volunteers. Altern Ther Health Med 2003: 9: 74–78
  42. Dhawan K et al. J Ethnopharmacol 2004:94: 1–23.
  43. Appel K, Rose T. Modulation of the g-Aminobutyric acid (GABA) system by Passiflora incarnata Phytother. Res. 2011: 25: 838–843
  44. Ingale A, Hivrale A. Pharmacological studies of Passiflor sp. and their bioactive compounds. Afr. J. Plant Sci. 2010: 4: 417–426
  45. Elsas SM, Rossi DJ. Passiflora incarnata L. (Passionflower) extracts elicit GABA currents in hippocampal neurons in vitro, and show anxiogenic and anticonvulsant effects in vivo, varying with extraction method. Phytomedicine. 2010 Oct;17(12):940-9
  46. Gazola AC, Costa GM. The sedative activity of flavonoids from Passiflora quadrangularis is mediated through the GABAergic pathway. Biomed Pharmacother. 2018 Apr;100:388-393
  47. Frankowska M, Filip M, Przegalinski E. x Effects of GABA-B receptor ligands in animal tests of depression and anxiety. Pharmacol Rep 2007:59: 645–655
  48. Grundmann O, Wang J. Activity of a phytochemically characterized passiflora incarnata extract is medicated bia the GABAergic system. Planta Med 2008; 74: 1769–1773
  49. Martin IL, Bowery NG et al. GABA receptors. Tocris Bioscience Scientific Review Series 2009:1–15.
  50. McKay DL, Blumberg JB. A review of the bioactivity and potential health benefits of chamomile tea (Matricaria recutita L.). Phytotherapy Research, 2006: 20(7): 519–530
  51. Redaelli C, Formentini L et al. Reversed-Phase high-performance liquid chromatography analysis of apigenin and its glucosides in flowers of Matricaria chamomilla and chamomile extracts. Planta Med 1981;42:288–292
  52. Avallone R, Zanoli P et al. Benzodiazepine‐like compounds and GABA in flower heads of Matricaria chamomilla. Phytotherapy Research, 1996: (10): S177–S179.
  53. Avallone R, Zanoli P et al. Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla. Biochemical Pharmacology, 2000: 59(11): 1387–1394
  54. Amsterdam JD, Li Y et al. A randomized, double‐blind, placebo‐controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. Journal of Clinical Psychopharmacology, 2009: 29(4): 378–382.
  55. Zick SM, Wright BD et al. Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: A randomized placebo‐controlled pilot study. BMC Complementary and Alternative Medicine, 2011: 11: 78–78.
  56. Reid, J. Minor Opus. Available at: https://www.spagyria.com/minor_opus/minor.php
  57. Spector AA, Yorek MA. Membrane lipid composition and cellular function. J Lipid Res. 1985 Sep;26(9):1015-35.
  58. Chang CY, Ke DS. Essential fatty acids and human brain. Acta Neurol Taiwan. 2009 Dec;18(4):231-41.
  59. Porter CJ. Drug delivery to the lymphatic system. Crit Rev Ther Drug Carrier Syst. 1997;14(4):333-93
  60. Ahn H, Park JH. Liposomal delivery systems for intestinal lymphatic drug transport. Biomater Res. 2016 Nov 23;20:36
  61. Alyautdin R, Khlain I et al. Nanoscale drug delivery systems and the blood brain barrier.  Int J Nanomedicine. 2014 Feb 7;9:795-811
Your Cart